Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
, 33 (1), 61-9

Validation of the Underlying Assumptions of the Quality-Adjusted Life-Years Outcome: Results From the ECHOUTCOME European Project


Validation of the Underlying Assumptions of the Quality-Adjusted Life-Years Outcome: Results From the ECHOUTCOME European Project

Ariel Beresniak et al. Pharmacoeconomics.


Background: Quality-adjusted life-years (QALYs) have been used since the 1980s as a standard health outcome measure for conducting cost-utility analyses, which are often inadequately labeled as 'cost-effectiveness analyses'. This synthetic outcome, which combines the quantity of life lived with its quality expressed as a preference score, is currently recommended as reference case by some health technology assessment (HTA) agencies. While critics of the QALY approach have expressed concerns about equity and ethical issues, surprisingly, very few have tested the basic methodological assumptions supporting the QALY equation so as to establish its scientific validity.

Objectives: The main objective of the ECHOUTCOME European project was to test the validity of the underlying assumptions of the QALY outcome and its relevance in health decision making.

Methods: An experiment has been conducted with 1,361 subjects from Belgium, France, Italy, and the UK. The subjects were asked to express their preferences regarding various hypothetical health states derived from combining different health states with time durations in order to compare observed utility values of the couples (health state, time) and calculated utility values using the QALY formula.

Results: Observed and calculated utility values of the couples (health state, time) were significantly different, confirming that preferences expressed by the respondents were not consistent with the QALY theoretical assumptions.

Conclusions: This European study contributes to establishing that the QALY multiplicative model is an invalid measure. This explains why costs/QALY estimates may vary greatly, leading to inconsistent recommendations relevant to providing access to innovative medicines and health technologies. HTA agencies should consider other more robust methodological approaches to guide reimbursement decisions.

Similar articles

See all similar articles

Cited by 8 PubMed Central articles

See all "Cited by" articles


    1. Int J Technol Assess Health Care. 1995 Winter;11(1):40-8 - PubMed
    1. Value Health. 2012 Dec;15(8):1172-81 - PubMed
    1. Soc Sci Med. 2009 Jan;68(2):362-7 - PubMed
    1. Pharmacoeconomics. 2002;20(7):463-73 - PubMed
    1. Pharmacoeconomics. 2003;21(14):991-1000 - PubMed

Publication types

LinkOut - more resources